<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551261</url>
  </required_header>
  <id_info>
    <org_study_id>PCD-DGLS4-20-001</org_study_id>
    <nct_id>NCT04551261</nct_id>
  </id_info>
  <brief_title>GLS4/RTV and TAF Drug-drug Interaction</brief_title>
  <official_title>A Phase I, Single-center, Open Label Clinical Study, to Evaluate the Pharmacokinetic Character of GLS4 Combined With RTV or TAF Alone or GLS4 and RTV and TAF Combination Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics&#xD;
      (PK) and tolerability of GLS4/RTV combined with TAF in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2-part study with each part is an open-label study in healthy adult subjects.&#xD;
&#xD;
      Total 28 subjects will be enrolled into the study and divided into 2 part (Part A and Part&#xD;
      B), 14 subjects in each part. With each part, the subject will be receive study drug per the&#xD;
      defined treatment periods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2021</start_date>
  <completion_date type="Actual">March 12, 2021</completion_date>
  <primary_completion_date type="Actual">March 12, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>predose to 96 hour after dosing</time_frame>
    <description>maximum observed plasma concentration of HEC96719</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>predose to 96 hour after dosing</time_frame>
    <description>area under the plasma concentration-time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event</measure>
    <time_frame>Baseline to day 22</time_frame>
    <description>To assess the safety and tolerability of therapy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive GLS4 and RTV on Day 1, TAF on Day 5-14, GLS4 and RTV and TAF on Day15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive TAF on Day 1, GLS4 and RTV on Day 5-14, GLS4 and RTV and TAF on Day15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLS4</intervention_name>
    <description>It is a new dihydropyrimidine antiviral drug that interferes the assembly of HBV core granule.</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RTV</intervention_name>
    <description>It is HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection;&#xD;
It is a CYP3A inhibitor combined with other drug to increase the exposure in human.</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
    <other_name>ritonavir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAF</intervention_name>
    <description>It is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
    <other_name>tenofovir alafenamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females, of any race, between 18 and 50 years of age, inclusive, at&#xD;
             Screening;&#xD;
&#xD;
          -  Body mass index between 18.0 and 28.0 kg/m2, inclusive, at Screening;&#xD;
&#xD;
          -  Females of childbearing potential and male subjects will agree to use contraception&#xD;
             from screening to the 6 months after the last administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In the 12 months prior to screening, observing clinical significance of the following&#xD;
             diseases, including but not limited to, gastrointestinal, kidney, liver, nerve, blood,&#xD;
             endocrine, tumor, lung, immune, mental, or cardio-cerebrovascular diseases;&#xD;
&#xD;
          -  Allergic constitution (multiple drug and food allergies);&#xD;
&#xD;
          -  A history of alcoholism;&#xD;
&#xD;
          -  Take any prescription drug, over-the-counter drug, vitamin product or herbal medicine&#xD;
             within 14 days of screening;&#xD;
&#xD;
          -  Any drug that changes the liver enzyme activity, such as barbiturates and Rifampicin,&#xD;
             was taken within 30 days before screening;&#xD;
&#xD;
          -  P-GP, BCRP, OATP1B1, OATP1B3, OAT1, OAT3 or MRP4 inhibitors or inducers, such as&#xD;
             azithromycin, pantoprazole or St. John's herb, etc., was taken within 30 days before&#xD;
             screening;&#xD;
&#xD;
          -  Female subjects are lactating or have positive blood pregnancy results during the&#xD;
             screening period;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

